Outcomes of haploidentical HCT trials with posttransplant cyclophosphamide published since 2018
| Reference . | Graft type . | No. of patients (age, y) . | Alive without SCD, No. . | Acute GVHD (grade 2-4), No. . | Chronic GVHD (moderate to severe), No. . | Death (cause), No. . |
|---|---|---|---|---|---|---|
| Frangoul et al27 | Primed BM or PBSC | 4 (12-23) | 4 | 4 (grade 2) | 0 | 0 |
| Saraf et al28 | PBSC | 8 (20-38) | 6 | 2 | 1 (moderate) | 1 (unknown) |
| Pawlowska et al29 | BM or PBSC | 4 (12-23) | 4 | 0 | 0 | 0 |
| de la Fuente et al30 | Primed BM | 15 (12-26) | 14 | 3 | 1 (moderate) | 0 |
| Bolaños-Meade et al31 | BM | 12 (6-31) | 10 | 29% (grade 2-3) | 1 (moderate) | 0 |
| Kassim et al32 | BM | 41 (1.3-43) | 36 | 4 | 5 (moderate) | 3 (infection) |
| Jaiswal et al33 | PBSC | 5 (8-19) | 5 | 0 | 0 | 0 |
| Oostenbrink et al34 | BM | 7 (1.8-17.5)a | 79%a | 25%a (grade 3-4) | 0 | 0 |
| Kharya et al35 | PBSC | 25 (1-27) | 22 | 5 | 0 | 3 (infection in 2, GVHD in 1) |
| Total | BM or PBSC | 121 | 88% | 19% (of total) | 7% (of total) | 6% |
| Reference . | Graft type . | No. of patients (age, y) . | Alive without SCD, No. . | Acute GVHD (grade 2-4), No. . | Chronic GVHD (moderate to severe), No. . | Death (cause), No. . |
|---|---|---|---|---|---|---|
| Frangoul et al27 | Primed BM or PBSC | 4 (12-23) | 4 | 4 (grade 2) | 0 | 0 |
| Saraf et al28 | PBSC | 8 (20-38) | 6 | 2 | 1 (moderate) | 1 (unknown) |
| Pawlowska et al29 | BM or PBSC | 4 (12-23) | 4 | 0 | 0 | 0 |
| de la Fuente et al30 | Primed BM | 15 (12-26) | 14 | 3 | 1 (moderate) | 0 |
| Bolaños-Meade et al31 | BM | 12 (6-31) | 10 | 29% (grade 2-3) | 1 (moderate) | 0 |
| Kassim et al32 | BM | 41 (1.3-43) | 36 | 4 | 5 (moderate) | 3 (infection) |
| Jaiswal et al33 | PBSC | 5 (8-19) | 5 | 0 | 0 | 0 |
| Oostenbrink et al34 | BM | 7 (1.8-17.5)a | 79%a | 25%a (grade 3-4) | 0 | 0 |
| Kharya et al35 | PBSC | 25 (1-27) | 22 | 5 | 0 | 3 (infection in 2, GVHD in 1) |
| Total | BM or PBSC | 121 | 88% | 19% (of total) | 7% (of total) | 6% |
BM, bone marrow; PBSC, peripheral blood stem cell.
Results reported for the combined group of 14 patients who underwent mismatched HCT: 7 haploidentical and 7 mismatched unrelated donors. Eleven patients had SCD and 3 β-thalassemia major.